Biotech, CRISPR, and Patent Law: Who Owns Life?
Introduction The field of biotechnology has experienced revolutionary advancements in recent years, with CRISPR-Cas9 technology standing at the forefront. This gene-editing tool allows scientists to make precise, targeted changes to the DNA of living organisms, opening up possibilities for treating genetic disorders, engineering crops, and even editing human embryos. However, along with these possibilities come profound legal and ethical questions about ownership, intellectual property, and the commodification of life itself. At the heart of this debate lies patent law. Who can claim ownership of genetic innovations? Should companies be allowed to patent living organisms or specific gene sequences? This article examines the intricate relationship between biotechnology, CRISPR, and patent law, exploring how the legal system grapples with the question: Who owns life? The Evolution of Biotech Patents Patent law has long been intertwined with biotechnology. In 1980, the U.S. Supreme Court...